What does this research mean for the field?

Anti-obesity pharmacotherapies, such as semaglutide and tirzepatide, offer disease-modifying benefits in obesity-related cardiovascular diseases, particularly heart failure with preserved ejection fraction, by improving functional capacity and attenuating cardiac remodeling. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review aims to evaluate the relationship between obesity and cardiovascular disease (CVD), focusing on therapeutic interventions.

July 12, 2026International Journal of Angiology

Document lists editorial board members for the International Journal of Angiology and contains no clinical data.

View Full Paper

Ask AI

Bookmark

Why the study?

Obesity has emerged as a major health challenge contributing substantially to the burden of cardiovascular disease.

Do anti-obesity pharmacotherapies like semaglutide and tirzepatide improve cardiovascular outcomes and symptoms in patients with obesity and cardiovascular disease?

Design

Integrative review of clinical trials, systematic reviews, and narrative reviews

Key result

This document is a list of editorial board members for the International Journal of Angiology and contains no clinical trial data.

Authors

PDPaul Duru VTVasiliki Tasouli-Drakou NRNoyan Ramazani

Discussion

Member takes

Overview

Supports semaglutide and tirzepatide in obese CVD patients; extends trial data on weight-independent benefits.

Key Points

This review aims to evaluate the relationship between obesity and cardiovascular disease (CVD), focusing on therapeutic interventions.
Synthesized findings from clinical trials, systematic reviews, and narrative reviews.
Assessed key outcomes including heart failure symptoms, echocardiographic parameters, and inflammation biomarkers.
Evaluated the effects of anti-obesity agents like semaglutide and tirzepatide.
Obesity linked to increased risk of coronary heart disease, atrial fibrillation, stroke, and heart failure with preserved ejection fraction.
Semaglutide and tirzepatide showed significant weight reduction and improved functional capacity, as well as reduced inflammation independent of weight loss.
Patients with atrial fibrillation and obesity experienced greater improvements with semaglutide compared to those without atrial fibrillation.

Structured PICO

Do anti-obesity pharmacotherapies like semaglutide and tirzepatide improve cardiovascular outcomes and symptoms in patients with obesity and cardiovascular disease?

Population

Patients with obesity and cardiovascular disease, including coronary heart disease, atrial fibrillation, stroke, and heart failure with preserved ejection fraction (HFpEF)

Intervention

Anti-obesity pharmacotherapies (semaglutide, tirzepatide, and other agents)

Outcome

Heart failure symptoms, echocardiographic parameters, incidence of atrial fibrillation, inflammation biomarkers, and overall cardiovascular morbidity and mortality

Anti-obesity pharmacotherapies represent a disease-modifying approach for obesity-related cardiovascular conditions, particularly HFpEF and AF.

Limitations

Heterogeneity in evidence regarding the obesity paradox
Confounding by differences in cardiorespiratory fitness and lead time biases

Cite This Study

Duru et al. (2026) reported an editorial. This document is a list of editorial board members for the International Journal of Angiology and contains no clinical trial data.

synapsesocial.com/papers/6a532f464f7abc118aded033 https://doi.org/10.1055/a-2904-8884

View Full Paper

Ask AI

Bookmark

July 12, 2026International Journal of Angiology

Document lists editorial board members for the International Journal of Angiology and contains no clinical data.

View Full Paper

Ask AI

Bookmark

Why the study?

Obesity has emerged as a major health challenge contributing substantially to the burden of cardiovascular disease.

Do anti-obesity pharmacotherapies like semaglutide and tirzepatide improve cardiovascular outcomes and symptoms in patients with obesity and cardiovascular disease?

Design

Integrative review of clinical trials, systematic reviews, and narrative reviews

Key result

This document is a list of editorial board members for the International Journal of Angiology and contains no clinical trial data.

Authors

PDPaul Duru VTVasiliki Tasouli-Drakou NRNoyan Ramazani

Discussion

Member takes

Overview

Supports semaglutide and tirzepatide in obese CVD patients; extends trial data on weight-independent benefits.

Key Points

This review aims to evaluate the relationship between obesity and cardiovascular disease (CVD), focusing on therapeutic interventions.
Synthesized findings from clinical trials, systematic reviews, and narrative reviews.
Assessed key outcomes including heart failure symptoms, echocardiographic parameters, and inflammation biomarkers.
Evaluated the effects of anti-obesity agents like semaglutide and tirzepatide.
Obesity linked to increased risk of coronary heart disease, atrial fibrillation, stroke, and heart failure with preserved ejection fraction.
Semaglutide and tirzepatide showed significant weight reduction and improved functional capacity, as well as reduced inflammation independent of weight loss.
Patients with atrial fibrillation and obesity experienced greater improvements with semaglutide compared to those without atrial fibrillation.

Structured PICO

Do anti-obesity pharmacotherapies like semaglutide and tirzepatide improve cardiovascular outcomes and symptoms in patients with obesity and cardiovascular disease?

Population

Patients with obesity and cardiovascular disease, including coronary heart disease, atrial fibrillation, stroke, and heart failure with preserved ejection fraction (HFpEF)

Intervention

Anti-obesity pharmacotherapies (semaglutide, tirzepatide, and other agents)

Outcome

Heart failure symptoms, echocardiographic parameters, incidence of atrial fibrillation, inflammation biomarkers, and overall cardiovascular morbidity and mortality

Anti-obesity pharmacotherapies represent a disease-modifying approach for obesity-related cardiovascular conditions, particularly HFpEF and AF.

Limitations

Heterogeneity in evidence regarding the obesity paradox
Confounding by differences in cardiorespiratory fitness and lead time biases

Cite This Study

Duru et al. (2026) reported an editorial. This document is a list of editorial board members for the International Journal of Angiology and contains no clinical trial data.

synapsesocial.com/papers/6a532f464f7abc118aded033 https://doi.org/10.1055/a-2904-8884

View Full Paper

Ask AI

Bookmark